Results 11 to 20 of about 5,421 (159)

Cefiderocol and Sulbactam-Durlobactam against Carbapenem-Resistant Acinetobacter baumannii [PDF]

Antibiotics, 2023
Infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB) remain a clinical challenge due to limited treatment options. Recently, cefiderocol, a novel siderophore cephalosporin, and sulbactam-durlobactam, a bactericidal β-lactam–β ...
Arta Karruli, Antonella Migliaccio, Spyros Pournaras, Emanuele Durante-Mangoni, Raffaele Zarrilli   +4 more
doaj   +7 more sources

Low-dose sulbactam-durlobactam for recurrent CRAB pneumonia in a child with cerebral palsy: a Case Report from a resource-limited setting [PDF]

Frontiers in Pharmacology
BackgroundPediatric data for sulbactam-durlobactam (SUL-DUR) are extremely scarce, and no standard pediatric dosing exists.MethodsWe report a 6-year-old boy with cerebral palsy and epilepsy who developed recurrent ventilator-associated pneumonia caused ...
Mengting Li, Mengting Li, Haotian Fei, Haotian Fei, Liang Huang, Liang Huang, Lu Qing, Lu Qing, Xiaoliang Liu, Xiaoliang Liu, Guoyan Lu, Guoyan Lu   +11 more
doaj   +3 more sources

In vitro activity of sulbactam-durlobactam against carbapenem-resistant Acinetobacter baumannii and mechanisms of resistance [PDF]

Journal of Global Antimicrobial Resistance, 2022
: Objectives: Multidrug-resistant Acinetobacter baumannii (MDR-Ab), particularly strains producing oxacillinase (OXA)-type carbapenemases, have rapidly emerged in health care settings as a frequent cause of serious infections with limited treatment ...
Jacqueline Findlay, Laurent Poirel, Maxime Bouvier, Patrice Nordmann   +3 more
doaj   +4 more sources

Sulbactam–Durlobactam: A Novel Antibiotic Combination for the Treatment of Acinetobacter baumannii–Calcoaceticus Complex (ABC) Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia [PDF]

Canadian Journal of Infectious Diseases and Medical Microbiology
Summary: Sulbactam–durlobactam is a recently approved antimicrobial combination of two β-lactamase inhibitors for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) associated with ...
Wissam K. Kabbara, Elina Sadek, Hanine Mansour   +2 more
doaj   +3 more sources

In Vitro Antibacterial Activity of Sulbactam-Durlobactam and Eravacycline Against Carbapenem-Resistant Acinetobacter baumannii in China and Analysis of Sulbactam-Durlobactam Resistance Mechanisms [PDF]

Polish Journal of Microbiology
The management of carbapenem-resistant Acinetobacter baumannii (CRAB) infections remains a formidable clinical challenge. This study evaluated the in vitro antimicrobial activities of sulbactam-durlobactam (SUL-DUR) and eravacycline (ERV) against CRAB ...
He Xuelian, Ma Shang, Zhou Yanyan, Wei Jingjuan, Zhuo Zhongling, Ma Liyan   +5 more
doaj   +3 more sources

In vitro activity of cefepime/zidebactam against sulbactam/durlobactam-susceptible and -resistant Acinetobacter baumannii clinical isolates. [PDF]

J Antimicrob Chemother
Abstract Objectives To evaluate the in vitro activity of cefepime in association with a β-lactamase inhibitor (enmetazobactam) or β-lactam enhancer (BLE), zidebactam, against carbapenem-resistant Acinetobacter baumannii (CRAB) strains susceptible or resistant to sulbactam/durlobactam.
Tascini C, Bianco G, Bonomo RA, Gaibani P.   +3 more
europepmc   +7 more sources

Antimicrobial activity of sulbactam-durlobactam against Acinetobacter baumannii-calcoaceticus complex strains causing non-respiratory and non-bloodstream infections from the United States (2023–2025) [PDF]

Microbiology Spectrum
Acinetobacter baumannii most often causes pneumonia in critically ill patients. However, A. baumannii is also an important cause of a broader range of infections, including skin/wound and urinary tract infections. This study aims to evaluate the in vitro
Elizabeth Cyr, Jill Argotsinger, Eric T. Beck, Robin R. Chamberland, Andrew E. Clark, Anne R. Daniels, Rachael Liesman, Mark Fisher, Philip Gialanella, Jonathan Hand, Amanda T. Harrington, Romney M. Humphries, Holly Huse, Robert Hamilton-Seth, Julia D. Hankins, Wesley D. Kufel, Scott W. Riddell, Meera Mehta, Ryan Demkowicz, A. Brian Mochon, Hossein Salimnia, Ayesha Khan, Virginia M. Pierce, Raghava Potula, Tsigereda Tekle, Patricia J. Simner, Robert J. Tibbetts, Christine Vu, Lilian M. Abbo, Octavio Martinez, Rebekah E. Dumm, Manohar B. Mutnal, Timothy C. Jenkins, Violeta Chávez, Paulette Pinargote, Jennifer Bowling, Erik Munson, Daniel V. Zurawski, David P. Nicolau, Tomefa E. Asempa   +39 more
doaj   +3 more sources

From clinical trials to daily practice: how to adequately administer sulbactam-durlobactam? alone or combined with imipenem? [PDF]

Curr Opin Infect Dis
Purpose of review Sulbactam-durlobactam (SUL-DUR) is a novel β-lactam/β-lactamase inhibitor combination recently approved for carbapenem-resistant Acinetobacter baumannii (CRAB) infections.
Bonazzetti C, Giannella M, Pascale R.
europepmc   +6 more sources

Durlobactam, a New Diazabicyclooctane β-Lactamase Inhibitor for the Treatment of Acinetobacter Infections in Combination With Sulbactam

Frontiers in Microbiology, 2021
Durlobactam is a new member of the diazabicyclooctane class of β-lactamase inhibitors with broad spectrum activity against Ambler class A, C, and D serine β-lactamases.
Samir Moussa, Adam Shapiro, Alita Miller   +2 more
exaly   +3 more sources

New Perspectives on Antimicrobial Agents: Sulbactam-durlobactam. [PDF]

Antimicrob Agents Chemother
ABSTRACT Infections due to Carbapenem-resistant Acinetobacter baumannii (CRAB) are a significant burden and are associated with devastating outcomes.
Pogue JM, Harrington J, Wangchinda W, Kaye KS.   +3 more
europepmc   +3 more sources